Geron Profile

2.25
USD 0.01  0.45%
11%
15%

Geron exotic insider transaction detected

Geron Corporation insider trading alert for general transaction of common stock by Olivia Bloom, EVP Chief Financial Officer, on August 14, 2017. This event was filed by Geron Corp with SEC on 2014-02-12. Statement of changes in beneficial ownership - SEC Form 4. Olivia Bloom is currently serves as cfo, executive vp of fin. and treasurer of Geron [view details]   

Geron Summary

Geron Corporation (GERN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 15 people. Geron is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 378.97 M. Geron Corporation conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 159.23 M outstanding shares of which 28.44 M shares are currently shorted by private and institutional investors with about 18.38 trading days to cover. GERON CORP currently holds about 96.89 M in cash with (16.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.61.
Check Geron Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected Geron Corporation Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Geron Against Markets

Risk Adjusted
Performance Score (0 to 100)
9 
Chance of
Financial Distress (0 to 100%)
< 80% 
Equity ratings for Geron Corporation are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
The company supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California. Geron operates under Biotechnology classification in USA and traded on NASDAQ exchange. It employs 15 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameGeron Corporation
President CEO, DirectorJohn ScarlettAll Leadership
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
RegionNorth America
LocationCALIFORNIA, U.S.A
Business Address149 Commonwealth Drive
ExchangeNASDAQ
CIK Number00886744.0
CUSIP374163103
SectorHealthcare
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.geron.com
Contact Number650 473 7700
CurrencyUSD - US Dollar

Recommendations

Geron Analyst Recommendations
Target PriceAdvice# of Analysts
4.17Buy3Odds
Geron Corporation current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Geron Analyst Advice  

Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Earnings

Geron Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.06March 1, 2017
Geron Corporation normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

Geron Corporate Directors
Daniel Bradbury Independent Director
Robert Spiegel Independent Director, Ph.D
Karin Eastham Independent Director, MBA